查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016220

即時檢測市場：2026-2032年全球市場預測（按產品類型、檢測類型、檢體類型、技術、便攜性、購買方式、應用、最終用戶和分銷管道分類）

Point of Care Testing Market by Product, Test Type, Sample Type, Technology, Portability, Mode of Purchase, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，即時檢測市場價值將達到 371.3 億美元，到 2026 年將成長至 419.9 億美元，到 2032 年將達到 907.6 億美元，年複合成長率為 13.61%。

主要市場統計數據
基準年 2025 371.3億美元
預計年份：2026年 419.9億美元
預測年份 2032 907.6億美元
複合年成長率 (%) 13.61%

該行業概覽清楚地說明了分散式診斷、先進檢測和數位融合如何重新定義臨床決策過程。

即時檢測（POC​​T）透過讓患者更方便地獲得及時的臨床決策，持續革新著我們的診斷方式。本文概述了當前即時檢測生態系統的現狀，重點關注分散式診斷、數位化連接和治療決策支援的融合。隨著醫療系統優先考慮快速分流、價值導向醫療和門診管理，即時檢測因其能夠減少臨床延誤並改善患者體驗而日益受到重視。

多參數檢測、互聯互通和醫療保健服務模式的進步如何融合起來，從而為分散式診斷實踐帶來系統性變革？

在技​​術、醫療服務模式和患者期望的共同驅動下，即時檢測領域正經歷著一場變革。首先，技術進步正推動檢測方式從快速單項分析轉向多參數檢測平台和整合分子診斷工作流程，從而拓展了現場診斷的範圍。同時，感測器的微型化和微流體技術的整合正在減少檢體用量和檢測時間，提高了居家和門診環境下應用的可行性。

評估美國於 2025 年推出的關稅措施對即時檢測相關人員的多方面營運和供應鏈影響。

美國2025年實施的關稅和貿易措施對即時檢測產業的製造商、供應商和終端用戶產生了複雜的影響。零件、耗材和成品的關稅推高了依賴全球供應鏈的產品總成本，可能影響籌資策略和補貨頻率。由於許多儀器和試劑都包含來自多個地區的電子元件、塑膠和精密加工零件，因此關稅導致的成本增加往往不均衡，並且取決於特定子組件的產地。

我們透過綜合細分分析來支援策略規劃，整合了產品、技術、測試類型、便攜性、購買方式、應用、最終用戶、檢體類型和分銷管道的趨勢。

細分洞察揭示了各個產品類型、測試類型、檢體基質、技術、便攜性選項、購買方式、應用、最終用戶和分銷管道如何塑造需求模式和發展重點。在產品細分中，耗材、服務和軟體、儀器和分析儀以及試劑和檢測方法各自具有不同的意義。耗材、配件、維護和校準服務以及軟體和連接性支援持續的收入來源和營運連續性。桌上型分析儀、分子診斷平台、可攜式分析儀和讀數器/掃描儀決定了部署方案和臨床工作流程。同時，血糖試紙、血液檢測試劑、免疫檢測試劑、橫向流動化驗試劑和分子診斷試劑盒驅動特定檢測方法的供應鏈和品質保證要求。

美洲、歐洲、中東和非洲以及亞太地區的地理差異如何影響照護現場的採購、監管和實施？

細微的區域差異顯著影響著就地檢驗的設計、實施和報銷方式，美洲、歐洲、中東、非洲和亞太地區各自擁有獨特的市場促進因素和營運考量。在美洲，醫療保健系統優先考慮門診最佳化和慢性病管理，因此對支持遠端監測以及在診所和家庭環境中快速進行心血管和代謝檢測的設備和檢測方法的需求日益成長。該地區的經銷網路優先考慮整合的供應鏈和本地化的服務支持，這使得能夠證明其擁有強大的售後服務以及與主流電子健康記錄系統數據互通性的製造商更具優勢。

策略性競爭行動和以平台為中心的創新決定了診斷生態系統的準備度、韌性和長期差異化。

即時檢測 (POCT) 領域的競爭格局以策略夥伴關係、平台差異化以及對整合儀器、耗材和軟體的整合解決方案的重視為特徵。主要企業優先考慮支援多種檢測形式的模組化平台架構，從而實現快速部署，並透過對耗材的持續需求提升產品生命週期價值。同時，與連接供應商和醫療 IT 整合商的合作對於提供可整合到臨床工作流程和社區健康促進舉措的數據豐富的診斷結果至關重要。

企業應實施切實可行的、高優先順序的策略措施，以確保診斷領域的應用、供應彈性和永續的商業性差異化。

為保持競爭力和臨床意義，產業領導企業應推動一系列務實舉措，使產品開發與實際營運狀況和不斷發展的醫療模式相契合。首先，應優先考慮互通性和以使用者為中心的軟體設計，確保儀器能夠無縫整合到臨床醫生的工作流程和電子健康記錄中，從而降低部署門檻。其次，應投資於模組化平台策略，以實現檢測的快速擴展和對多種檢體類型的支持，從而提高採購團隊的柔軟性，並減少部署多台儀器的需求。

採用透明且可重複的研究途徑，結合對關鍵相關人員的訪談、嚴格的二手文獻綜述和資料三角驗證，以檢驗結論。

本分析的調查方法融合了定性和定量方法，旨在確保研究的嚴謹性、相關性和可重複性。主要研究工作包括對醫療專業人員、實驗室負責人以及設備製造商和分銷商的高級管理人員進行深入訪談，以了解實際應用案例、採購限制和尚未解決的需求。此外，也輔以現場觀察和工作流程整合點的檢驗，將臨床優先事項轉化為產品需求。

一項旨在實現快速診斷、營運彈性和嚴格品管之間平衡的最終整合方案，以產生臨床影響。

總之，即時檢測正處於轉折點，由於技術成熟、醫療服務模式的變革和政策的調整，診斷路徑正在重新定義。檢測化學、儀器小型化和軟體連接性的進步推動了去中心化診斷的普及，但這種轉變也帶來了營運、監管和供應鏈方面的挑戰，需要認真考慮。關稅措施、採購優先事項的轉變以及區域監管差異進一步增加了複雜性，相關人員必須透過彈性採購、適應性強的產品架構和可靠的證據來應對這些挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 即時檢測市場：依產品分類

  • 耗材、服務和軟體
    • 耗材和配件
    • 維護和校準
    • 軟體和連接功能
  • 儀器/分析儀
    • 桌上型分析儀
    • 分子診斷平台
    • 可攜式分析儀
    • 閱讀器和掃描儀
  • 試劑和測定
    • 血糖試紙
    • 血液檢測試劑
    • 免疫檢測試劑
    • 橫向流動化驗試劑
    • 分子診斷試劑盒

第9章 依檢測類型分類的即時檢測市場

  • 血氣分析
  • 心臟標記物
    • B型鈉尿肽
    • 肌鈣蛋白
  • 綜合代謝指標
  • 藥物濫用檢測
  • 血液學
    • 血液凝固檢驗
      • 活化部份凝血活酵素時間
      • 纖維蛋白原水平
      • 凝血酶原時間與國際標準化比值
    • 血液常規檢查
  • 感染疾病
    • 胃腸道傳染病檢查
    • 呼吸道傳染病檢查
    • 性行為感染感染檢測
  • 分子診斷
  • 懷孕與不孕
  • 尿液檢查

第10章 依檢體類型分類的即時偵測市場

  • 血
  • 鼻腔和棉花棒檢體
  • 唾液
  • 尿

第11章 即時偵測市場：依技術分類

  • 生物感測器（電化學公式）
  • 比色平台
  • 免疫檢測
  • 橫向流動化驗
    • 抗體檢測
    • 抗原檢測
    • 多側向流
  • 微流體技術
  • PCR和分子診斷

第12章 即時檢測市場：攜帶式

  • 固定式分析儀
  • 攜帶式手持設備

第13章 依購買方式分類的即時偵測市場

  • 市售檢測套組
  • 處方箋處方檢測

第14章 即時檢測市場：依應用領域分類

  • 慢性病管理
  • 急診/重症監護
  • 感染疾病診斷
  • 職業和職場測試
  • 腫瘤監測
  • 女性健康

第15章 即時檢測市場：依最終用戶分類

  • 門診部
  • 診斷檢查室
  • 獨立急診科
  • 居家照護
  • 醫院和診所
  • 急診中心

第16章 即時偵測市場：依通路分類

  • 離線
    • 直銷
    • 銷售代理商和批發商
    • 零售和藥房
  • 線上

第17章 即時檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章 即時偵測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 即時偵測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國即時檢測市場

第21章：中國的即時檢測市場

第22章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • Danaher Corporation
  • EKF Diagnostics Holdings
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare Technologies, Inc.
  • Medtronic Plc
  • Nova Biomedical Corporation
  • OraSure Technologies, Inc.
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035AB9C0DA8B

The Point of Care Testing Market was valued at USD 37.13 billion in 2025 and is projected to grow to USD 41.99 billion in 2026, with a CAGR of 13.61%, reaching USD 90.76 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.13 billion
Estimated Year [2026] USD 41.99 billion
Forecast Year [2032] USD 90.76 billion
CAGR (%) 13.61%

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Point of Care Testing Market, by Product

  • 8.1. Consumables Services & Software
    • 8.1.1. Consumables & Accessories
    • 8.1.2. Service Maintenance & Calibration
    • 8.1.3. Software & Connectivity
  • 8.2. Instruments & Analyzers
    • 8.2.1. Benchtop Analyzers
    • 8.2.2. Molecular Platforms
    • 8.2.3. Portable Analyzers
    • 8.2.4. Readers & Scanners
  • 8.3. Reagents & Assays
    • 8.3.1. Glucose Test Strips
    • 8.3.2. Hematology Reagents
    • 8.3.3. Immunoassay Reagents
    • 8.3.4. Lateral Flow Assay Reagents
    • 8.3.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

  • 9.1. Blood Gases
  • 9.2. Cardiac Markers
    • 9.2.1. B-type Natriuretic Peptide
    • 9.2.2. Troponin
  • 9.3. Comprehensive Metabolic Panel
  • 9.4. Drug Of Abuse Testing
  • 9.5. Hematology
    • 9.5.1. Coagulation Tests
      • 9.5.1.1. Activated Partial Thromboplastin Time
      • 9.5.1.2. Fibrinogen Level
      • 9.5.1.3. Prothrombin Time & International Normalized Ratio
    • 9.5.2. Complete Blood Count
  • 9.6. Infectious Disease
    • 9.6.1. Gastrointestinal Infection Tests
    • 9.6.2. Respiratory Infection Tests
    • 9.6.3. Sexually Transmitted Infection Tests
  • 9.7. Molecular Diagnostics
  • 9.8. Pregnancy & Fertility
  • 9.9. Urinalysis

10. Point of Care Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Nasal & Swab Samples
  • 10.3. Saliva
  • 10.4. Urine

11. Point of Care Testing Market, by Technology

  • 11.1. Biosensor Electrochemical
  • 11.2. Colorimetric Platforms
  • 11.3. Immunoassay
  • 11.4. Lateral Flow Assays
    • 11.4.1. Antibody Tests
    • 11.4.2. Antigen Tests
    • 11.4.3. Multiplex Lateral Flow
  • 11.5. Microfluidics
  • 11.6. PCR And Molecular

12. Point of Care Testing Market, by Portability

  • 12.1. Benchtop Fixed Analyzers
  • 12.2. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

  • 13.1. Over-The-Counter Tests
  • 13.2. Prescription-Based Tests

14. Point of Care Testing Market, by Application

  • 14.1. Chronic Disease Management
  • 14.2. Emergency And Critical Care
  • 14.3. Infectious Disease Diagnosis
  • 14.4. Occupational And Workplace Testing
  • 14.5. Oncology Monitoring
  • 14.6. Women Health

15. Point of Care Testing Market, by End User

  • 15.1. Ambulatory Care Centers
  • 15.2. Diagnostic Laboratories
  • 15.3. Free-Standing Emergency Departments
  • 15.4. Home Care
  • 15.5. Hospitals & Clinics
  • 15.6. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

  • 16.1. Offline
    • 16.1.1. Direct Sales
    • 16.1.2. Distributor & Wholesale
    • 16.1.3. Retail & Pharmacy
  • 16.2. Online

17. Point of Care Testing Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Point of Care Testing Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Point of Care Testing Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Point of Care Testing Market

21. China Point of Care Testing Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abaxis, Inc. by Zoetis Inc
  • 22.6. Abbott Laboratories
  • 22.7. AccuBioTech Co., Ltd.
  • 22.8. ACON Laboratories, Inc.
  • 22.9. Beckman Coulter
  • 22.10. Becton, Dickinson and Company
  • 22.11. Bio-Rad Laboratories, Inc.
  • 22.12. bioMerieux SA
  • 22.13. CardioGenics Holdings Inc.
  • 22.14. Chembio Diagnostic Systems, Inc. by Biosynex
  • 22.15. Danaher Corporation
  • 22.16. EKF Diagnostics Holdings
  • 22.17. F. Hoffmann-La Roche Ltd
  • 22.18. GE Healthcare Technologies, Inc.
  • 22.19. Medtronic Plc
  • 22.20. Nova Biomedical Corporation
  • 22.21. OraSure Technologies, Inc.
  • 22.22. Quidel Corporation
  • 22.23. Radiometer Medical ApS
  • 22.24. Randox Laboratories Ltd.
  • 22.25. Siemens Healthineers AG
  • 22.26. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 278. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET